Purdue's Sacklers consider adding another $1 billion to opioid settlement - Bloomberg News
Reuters
Published Feb 10, 2022 09:52PM ET
Updated Feb 10, 2022 10:10PM ET
(Reuters) - Members of the billionaire Sackler family that owns Purdue Pharma are weighing whether to add $1 billion to the OxyContin-maker's faltering opioid settlement bid in an effort to win over holdouts, Bloomberg News reported on Thursday.
The addition would bring the family's total contribution to $5.325 billion to get a handful of U.S. state attorneys general to drop their opposition to Purdue's bankruptcy plan, the report said citing people familiar with the matter.
Purdue did not immediately respond to a request for comment.
Earlier this week, a mediator reported that the OxyContin-maker and U.S. states were "even closer" to a settlement over claims that the company fueled a U.S. opioid epidemic.
The mediator asked a bankruptcy judge to extend the deadline for negotiations to Feb. 16 from Feb. 7, saying that the two sides need more time to finalize a deal that would involve "substantial" additional money from the Sacklers. The new settlement would also include non-monetary concessions.
Purdue, the maker of the highly addictive opioid pain drug OxyContin, filed for bankruptcy in 2019 in the face of thousands of lawsuits accusing it and wealthy Sackler family members who owned the company of helping cause the U.S. opioid epidemic through deceptive marketing that played down addiction and overdose risks.
The company pleaded guilty to misbranding and fraud charges related to its marketing of OxyContin in 2007 and 2020. The Sacklers have denied wrongdoing.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.